Victory Capital Management
RNTX

Victory Capital Management’s Rein Therapeutics RNTX Stock Holding History

Victory Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-520
Closed -$13K – 2865
2021
Q2 		$13K Sell
520
-23
-4% -$574 ﹤0.01% 2723
2021
Q1 		$16K Buy
+543
New +$18.6K ﹤0.01% 2727
2020
Q2 		– Sell
-342
Closed -$2K – 3344
2020
Q1 		$2K Buy
+342
New +$4.12K ﹤0.01% 3690
2019
Q4 		– Sell
-146
Closed -$2K – 3333
2019
Q3 		$2K Buy
+146
New +$2.02K ﹤0.01% 3654

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management's RNTX Position: Q3 2021 in Review

Victory Capital Management sold out of Rein Therapeutics (RNTX) in Q3 2021, closing a stake of 520 shares — an estimated $13K sold.

Victory Capital Management first reported a position in RNTX in Q3 2019 and held it in 4 quarters. The position peaked at $16K in Q1 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q3 2021.

  • Victory Capital Management reported no remaining Rein Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Victory Capital Management sold 520 Rein Therapeutics shares in Q3 2021, an estimated $13K.
  • Victory Capital Management first reported a position in Rein Therapeutics in Q3 2019 and held it in 4 quarters.
  • Victory Capital Management's Rein Therapeutics position peaked at $16K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2021.

Based on Victory Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.